awmsg logo



mycophenolic acid (Myfortic®)


Reference No. 210

Publication date:
13/06/2006


Appraisal information

mycophenolic acid (Myfortic®) tablet


Company: Novartis Pharmaceuticals UK Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: 02/03/2006
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: Not available
Ministerial ratification: 07/06/2006

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

The use of mycophenolate sodium (Myfortic®) within NHS Wales should be supported for the prophylaxis (in combination with ciclosporin and corticosteroids) of acute (transplant) rejection in adults receiving allogenic renal transplants, and who are intolerant of mycophenolate mofetil. Its use should be under the supervision of a nephrologist.
Final Appraisal Recommendation (FAR)
Download